ストックスクリーナーアプリを入手
23.50
1.59%
-0.38
アフターアワーズ：
22.10
-1.40
-5.96%
前日終値:
$23.88
開ける：
$23.96
24時間の取引高:
1.88M
Relative Volume:
0.79
時価総額：
$2.27B
収益：
$610.16M
当期純損益:
$-532.93M
株価収益率:
-4.2505
EPS:
-5.5287
ネットキャッシュフロー:
$-442.30M
1週間 パフォーマンス:
-1.22%
1か月 パフォーマンス:
-3.57%
6か月 パフォーマンス:
-16.40%
1年 パフォーマンス:
-45.89%
1日の値動き範囲:
$22.93
$24.35
1週間の範囲:
$22.93
$24.87
52週間の値動き範囲:
$18.41
$46.27
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
23.50 | 2.30B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com
Ultragenyx (RARE) Revenue Forecasts Highlight Crysvita and Dojolvi Growth - GuruFocus
Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts - marketscreener.com
Ultragenyx shares fall as 2026 revenue guidance misses expectations By Investing.com - Investing.com India
Ultragenyx shares fall as 2026 revenue guidance misses expectations - Investing.com
Ultragenyx Pharmaceutical Inc. Sued for Securities Law - GlobeNewswire
Ultragenyx (RARE) Q4 Revenue Surpasses Expectations, Prepares fo - GuruFocus
Ultragenyx Pharma Loss Narrows; To Cut 10% Of Workforce - Nasdaq
Ultragenyx: Q4 Earnings Snapshot - wwltv.com
Ultragenyx Launches Restructuring Plan to Cut Costs - TipRanks
Ultragenyx Pharmaceutical Q4 Earnings Report: What Investors Need to Know - Benzinga
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update - GlobeNewswire
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsRARE - PR Newswire
RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE) - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Ultragenyx earnings in focus as gene therapy hopes offset drug flop - Investing.com Nigeria
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx: Fourth Quarter Financial Overview - bitget.com
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical - Intellectia AI
Class Action Announcement for Ultragenyx Pharmaceutical - GlobeNewswire
Earnings Outlook For Ultragenyx Pharmaceutical - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law - GlobeNewswire
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve
Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Ultragenyx Pharmaceutical Inc. (RARE): Investor Outlook Reveals a Promising 168% Potential Upside - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Se - PharmiWeb.com
RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. - The AI Journal
Stock Traders Buy Large Volume of Ultragenyx Pharmaceutical Put Options (NASDAQ:RARE) - MarketBeat
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Ultragenyx Pharmaceutical Inc. (RARE) - marketscreener.com
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP AnnouncesRARE - PR Newswire
Candriam S.C.A. Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit - The Malaysian Reserve
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Caledonian Record
RARE Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies - BioSpace
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
Ultragenyx Pharmaceutical Class Action Lawsuit Announced - Intellectia AI
Ultragenyx Pharmaceutical (RARE) resubmits biologics license application for gene therapy treatment - MSN
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
RARE SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
Quant snapshot: Manulife, KBC, Ambev lead strong buys as Ultragenyx, Atomera lag - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
2026-02-08 | RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
INVESTOR NOTICE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment - Finviz
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):